|
1
|
Mathur N and Ghosh PS: Schwartz-jampel
syndrome. Pediatr Neurol. 68:77–78. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nicole S, Davoine CS, Topaloglu H,
Cattolico L, Barral D, Beighton P, Hamida CB, Hammouda H, Cruaud C,
White PS, et al: Perlecan, the major proteoglycan of basement
membranes, is altered in patients with Schwartz-Jampel syndrome
(chondrodystrophic myotonia). Nat Genet. 26:480–483. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jablecki C and Schultz P: Single muscle
fiber recordings in the Schwartz-Jampel syndrome. Muscle Nerve.
5:S64–S69. 1982.PubMed/NCBI
|
|
4
|
Arikawa-Hirasawa E, Le AH, Nishino I,
Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney
JM, Spranger J, et al: Structural and functional mutations of the
perlecan gene cause Schwartz-Jampel syndrome, with myotonic
myopathy and chondrodysplasia. Am J Hum Genet. 70:1368–1375. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodgers KD, Sasaki T, Aszodi A and Jacenko
O: Reduced perlecan in mice results in chondrodysplasia resembling
Schwartz-Jampel syndrome. Hum Mol Genet. 16:515–528. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kashkouli MB, Shahrzad S, Jazayeri AA and
Abtahi MB: Treatment of blepharospasm in schwartz-jampel syndrome:
Botulinum toxin A injection or surgery. Ophthal Plast Reconstr
Surg. 33 3S Suppl 1:S47–S49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stum M, Girard E, Bangratz M, Bernard V,
Herbin M, Vignaud A, Ferry A, Davoine CS, Echaniz-Laguna A, René F,
et al: Evidence of a dosage effect and a physiological endplate
acetylcholinesterase deficiency in the first mouse models mimicking
Schwartz-Jampel syndrome neuromyotonia. Hum Mol Genet.
17:3166–3179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kallunki P, Eddy RL, Byers MG, Kestilä M,
Shows TB and Tryggvason K: Cloning of human heparan sulfate
proteoglycan core protein, assignment of the gene (HSPG2) to
1p36.1–p35 and identification of a BamHI restriction fragment
length polymorphism. Genomics. 11:389–396. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dodge GR, Kovalszky I, Chu ML, Hassell JR,
McBride OW, Yi HF and Iozzo RV: Heparan sulfate proteoglycan of
human colon: Partial molecular cloning, cellular expression, and
mapping of the gene (HSPG2) to the short arm of human chromosome 1.
Genomics. 10:673–680. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stum M, Davoine CS, Vicart S, Guillot-Noël
L, Topaloglu H, Carod-Artal FJ, Kayserili H, Hentati F, Merlini L,
Urtizberea JA, et al: Spectrum of HSPG2 (Perlecan) mutations in
patients with Schwartz-Jampel syndrome. Hum Mutat. 27:1082–1091.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spranger J, Hall BD, Häne B, Srivastava A
and Stevenson RE: Spectrum of Schwartz-Jampel syndrome includes
micromelic chondrodysplasia, kyphomelic dysplasia, and Burton
disease. Am J Med Genet. 94:287–295. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kelley LA and Sternberg MJ: Protein
structure prediction on the Web: A case study using the Phyre
server. Nat Protoc. 4:363–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iwata S, Ito M, Nakata T, Noguchi Y, Okuno
T, Ohkawara B, Masuda A, Goto T, Adachi M, Osaka H, et al: A
missense mutation in domain III in HSPG2 in Schwartz-Jampel
syndrome compromises secretion of perlecan into the extracellular
space. Neuromuscul Disord. 25:667–671. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Das Bhowmik A, Dalal A, Matta D, Kandadai
RM, Kanikannan MA and Aggarwal S: Identification of a novel splice
site HSPG2 mutation and prenatal diagnosis in Schwartz Jampel
Syndrome type 1 using whole exome sequencing. Neuromuscul Disord.
26:809–814. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shah M and Scavina M: Novel mutations in
Schwartz-Jampel syndrome with successes in medical management.
Neurology. 84 Suppl 14:(P2): 2372015.
|
|
17
|
Giedion A, Boltshauser E, Briner J, Eich
G, Exner G, Fendel H, Kaufmann L, Steinmann B, Spranger J and
Superti-Furga A: Heterogeneity in Schwartz-Jampel chondrodystrophic
myotonia. Eur J Pediatr. 156:214–223. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arikawa-Hirasawa E, Le AH, Nishino I,
Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney
JM, Spranger J, et al: Structural and functional mutations of the
perlecan gene cause Schwartz-Jampel syndrome, with myotonic
myopathy and chondrodysplasia. Am J Hum Genet. 70:1368–1375. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lim BC, Yoo SK, Lee S, Shin JY, Hwang H,
Chae JH, Hwang YS, Seo JS, Kim JI and Kim KJ: Hoyeraal-Hreidarsson
syndrome with a DKC1 mutation identified by whole-exome sequencing.
Gene. 546:425–429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mansouri M, Kayserili H, Elalaoui SC,
Nishimura G, Iida A, Lyahyai J, Miyake N, Matsumoto N, Sefiani A
and Ikegawa S: Novel DDR2 mutation identified by whole exome
sequencing in a Moroccan patient with spondylo-meta-epiphyseal
dysplasia, short limb-abnormal calcification type. Am J Med Genet
A. 170A:460–465. 2016. View Article : Google Scholar : PubMed/NCBI
|
